BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

BioNTech shares are crashing as the company posted a disappointing Q4 release and announced cofounders departure by the end of 2026. Here’s why BNTX stock is still worth buying today.

BioNTech SE (BNTX) on Tuesday revealed plans to launch a separate biotechnology venture dedicated to advancing ...

BioNTech SE BNTX shares are down during Tuesday’s premarket session as the company announced plans for its co-founders to transition into a new venture focused on next-generation mRNA innovations.

We have seen 128 institutional investors add shares of $BNTX stock to their portfolio, and 130 decrease their positions in their most recent quarter.

If you are wondering whether BioNTech is starting to look like value after the Covid vaccine boom faded, or if the current ...

BioNTech (BNTX) reported upbeat Q4 results and FY26 sales guidance below estimates. Shares gained 7.7% on Wednesday. Analysts have mixed opinions.

BioNTech (BNTX) stock tumbles 17% after reporting Q4 losses, missing 2026 revenue projections, and announcing co-founder departures. Full analysis here.

We came across a bullish thesis on BioNTech SE on Lux Opes Research’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $118.00 as of January ...

We have seen 119 institutional investors add shares of $BNTX stock to their portfolio, and 192 decrease their positions in their most recent quarter.